Carotid atherosclerotic plaque stenosis: The stabilizing role of statins

European Journal of Clinical Investigation

Volumn 44, Issue 11, 2014, Pages 1122-1134

  Artom, Nathan ^a   Montecucco, Fabrizio ^a,b,c   Dallegri, Franco ^a   Pende, Aldo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Atherosclerosis; Carotid plaque; Inflammation; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ATHEROGENESIS; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; COMMON CAROTID ARTERY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; CAROTID STENOSIS; PLAQUE, ATHEROSCLEROTIC; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CAROTID INTIMA-MEDIA THICKNESS; CAROTID STENOSIS; CORONARY ARTERY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MAGNETIC RESONANCE IMAGING; PLAQUE, ATHEROSCLEROTIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84925946149     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12340     Document Type: Review

References (122)

1. Rockman CB, Hoang H, Guo Y, Maldonado TS, Jacobowitz GR, Talishinskiy T et al. The prevalence of carotid artery stenosis varies significantly by race. J Vasc Surg 2013;57:327-37.
2. Beckman JA. Management of asymptomatic internal carotid artery stenosis. JAMA 2013;310:1612-8.
3. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2: a double-blind, placebo controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-7.
4. Lee JM, Robson MD, Yu LM, Shirodaria CC, Cunnington C, Kylintireas I et al. Effects of high dose modified release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787-94.
5. Sibley CT, Vavere AL, Gottlieb I, Cox C, Matheson M, Spooner A et al. MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart 2013;99:1675-80.
6. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43.
7. West AM, Anderson JD, Meyer CH, Epstein FH, Wang H, Hagspiel KD et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis 2011;218:156-62.
8. Bogiatzi C, Spence JD. Ezetimibe and regression of carotid atherosclerosis: importance of measuring plaque burden. Stroke 2012;43:1153-5.
9. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22.
10. Taylor AJ, Villines TC, Stanek EJ. Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe. Eur Heart J 2012;33:1939-45.
11. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30.
12. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153-60.
13. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317-25.
14. Markl M, Wegent F, Zech T, Bauer S, Strecker C, Schumacher M et al. In vivo wall shear stress distribution in the carotid artery: effect of bifurcation geometry, internal carotid artery stenosis, and recanalization therapy. Circ Cardiovasc Imaging 2010;3:647-55.
15. Montecucco F, Lenglet S, Gayet-Ageron A, Bertolotto M, Pelli G, Palombo D et al. Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. Stroke 2010;41:1394-404.
16. Montecucco F, Di Marzo V, da Silva RF, Vuilleumier N, Capettini L, Lenglet S et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 2012;33:846-56.
17. Montecucco F, Vuilleumier N, Pagano S, Lenglet S, Bertolotto M, Braunersreuther V et al. Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011;32:412-21.
18. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986;74:1399-406.
19. Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis. Atherosclerosis 2012;220:128-33.
20. Finn AV, Kolodgie FD, Virmani R. Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. Arterioscler Thromb Vasc Biol 2010;30:177-81.
21. Spence JD. Technology insight: ultrasound measurement of carotid plaque - patient management, genetic research, and therapy evaluation. Nat Clin Pract Neurol 2006;2:611-9.
22. Spence JD, Eliasziw M, DiCicco M, Hackam DG, Galil R, Lohmann T. Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke 2002;33:2916-22.
23. Wannarong T, Parraga T, Buchanan D, Fenster A, House AA, Hackam DG et al. Progression of carotid plaque volume predicts cardiovascular events. Stroke 2013;44:1859-65.
24. Kitamura A, Iso H, Imano H, Ohira T, Okada T, Sato S et al. Carotid intima-media thickness and plaque characteristics as a risk factor for stroke in Japanese elderly men. Stroke 2004;35:2788-94.
25. Prabhakaran S, Rundek T, Ramas R, Elkind MS, Paik MC, Boden-Albala B et al. Carotid plaque surface irregularity predicts ischemic stroke: the northern Manhattan study. Stroke 2006;37:2696-701.
26. Ylä-Herttuala S, Bentzon JF, Daemen M, Falk E, Garcia-Garcia HM, Herrmann J et al. Stabilization of atherosclerotic plaques: an update. Eur Heart J 2013;34:3251-8.
27. European Carotid Plaque Study Group. Carotid artery plaque composition - relationship to clinical presentation and ultrasound B-mode imaging. Eur J Vasc Endovasc Surg 1995;10:23-30.
28. El-Barghouty NM, Levine T, Ladva S, Flanagan A, Nicolaides A. Histological verification of computerized plaque characterization. Eur J Vasc Endovasc Surg 1996;11:414-6.
29. Grønholdt ML, Nordestgaard BG, Schroeder T, Vorstrup S, Sillesen H. Ultrasonic echolucent carotid plaques predict future strokes. Circulation 2001;104:68-73.
30. Mathiesen EB, Bonaa KH, Joakimsen O. Echolucent plaque are associated with high risk of ischemic cerebrovascular events in carotid stenosis. The Tromsø Study. Circulation 2001;103:2171-5.
31. Grønholdt ML, Nordestgaard BG, Bentzon J, Wiebe BM, Zhou J, Falk E et al. Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging and elevated plasma lipid levels. J Vasc Surg 2002;35:137-45.
32. Ringelstein EB, Droste DW, Babikian VL, Evans DH, Grosset DG, Kaps M et al. Consensus on microembolus detection by TCD. International Consensus Group on Microembolus Detection. Stroke 1998;29:725-9.
33. Spence JD, Tamayo A, Lownie SP, Ng WP, Ferguson GG. Absence of microemboli on transcranial Doppler identifies low-risk patients with asymptomatic carotid stenosis. Stroke 2005;36:2373-8.
34. Markus HS, King A, Shipley M, Topakian R, Cullinane M, Reihill S et al. Asymptomatic embolisation for prediction of stroke in the Asymptomatic Carotid Emboli Study (ACES): a prospective observational study. Lancet Neurol 2010;9:663-71.
35. Topakian R, King A, Kwon SU, Schaafsma A, Shipley M, Markus HS, ACES Investigators. Ultrasonic plaque echolucency and emboli signals predict stroke in asymptomatic carotid stenosis. Neurology 2011;77:751-8.
36. Madani A, Beletsky V, Tamayo A, Munoz C, Spence JD. High-risk asymptomatic carotid stenosis: ulceration on 3D ultrasound vs TCD microemboli. Neurology 2011;77:744-50.
37. Saba L, Anzidei M, Sanfilippo R, Montisci R, Lucatelli P, Catalano C et al. Imaging of the carotid artery. Atherosclerosis 2012;220:294-309.
38. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006;48:1818-24.
39. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol 2007;50:892-6.
40. Palm F, Dos Santos M, Urbanek C, Greulich M, Zimmer K, Safer A et al. Stroke seasonality associations with subtype, etiology and laboratory results in the Ludwigshafen Stroke Study (LuSSt). Eur J Epidemiol 2013;28:373-81.
41. Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke 2009;40:e573-83.
42. Marquardt L, Geraghty OC, Mehta Z, Rothwell PM. Low risk of ipsilateral stroke in patients with asymptomatic carotid stenosis on best medical treatment: a prospective, population-based study. Stroke 2010;41:e11-7.
43. Raman G, Moorthy D, Hadar N, Dahabreh IJ, O'Donnell TF, Thaler DE et al. Management strategies for asymptomatic carotid stenosis: a systematic review and meta-analysis. Ann Intern Med 2013;158:676-85.
44. Spence JD. Asymptomatic carotid stenosis. Circulation 2013;127:739-42.
45. Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol 2010;55:1600-7.
46. Nambi V, Chambless L, He M, Folsom AR, Mosley T, Boerwinkle E et al. Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. Eur Heart J 2012;33:183-90.
47. Lorenz MW, Schaefer C, Steinmetz H, Sitzer M. Is carotid intima media thickness useful for individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS). Eur Heart J 2010;31:2041-8.
48. Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, Völzke H, Tuomainen TP et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012;379:2053-62.
49. Nambi V, Brunner G, Ballantyne CM. Ultrasound in cardiovascular risk prediction: don't forget the plaque!. J Am Heart Assoc 2013;2:e000180.
50. Sillesen H, Muntendam P, Adourian A, Entrekin R, Garcia M, Falk E et al. Carotid plaque burden as a measure of subclinical atherosclerosis: comparison with other tests for subclinical arterial disease in the High Risk Plaque BioImage study. JACC Cardiovasc Imaging 2012;5:681-9.
51. Spence JD. Point: uses of carotid plaque measurement as a predictor of cardiovascular events. Prev Cardiol 2005;8:118-21.
52. Spence JD, Hackam DG. Treating arteries instead of risk factors: a paradigm change in management of atherosclerosis. Stroke 2010;41:1193-9.
53. Young W, Gofman JW, Tandy R, Malamud N, Waters ES. The quantitation of atherosclerosis. II. Quantitative aspects of the relationship of blood pressure and atherosclerosis. Am J Cardiol 1960;6:294-9.
54. Spence JD, Hegele RA. Noninvasive phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:e188.
55. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008;21:93-111.
56. Myers GL, Rifai N, Tracy R, Roberts WL, Alexander RW, Biasucci LM et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease. Circulation 2004;100:545-9.
57. Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events. The St Francis Heart Study. J Am Coll Cardiol 2005;46:158-65.
58. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham Score for the risk prediction in asymptomatic individuals. JAMA 2004;291:210-5.
59. Brook RD, Bard RL, Patel S, Rubenfire M, Clarke NS, Kazerooni EA et al. A negative carotid plaque area test is superior to other noninvasive atherosclerosis studies for reducing the likelihood of having underlying significant coronary artery disease. Arterioscler Thromb Vasc Biol 2006;26:656-62.
60. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
61. Makris GC, Lavida A, Nicolaides AN, Geroulakos G. The effect of statins on carotid plaque morphology: a LDL-associated action or one more pleiotropic effect of statins? Atherosclerosis 2010;213:8-20.
62. Antonopulous AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012;18:1519-30.
63. Blaha MJ, Martin SS. How do statins work?: changing paradigms with implications for statin allocation. J Am Coll Cardiol 2013;62:2392-4.
64. Montecucco F, Burger F, Pelli G, Poku NK, Berlier C, Steffens S et al. Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology (Oxford) 2009;48:233-42.
65. Cirillo P, Pacileo M, De Rosa S, Calabrò P, Gargiulo A, Angri V et al. HMG-CoA reductase inhibitors reduce nicotine-induced expression of cellular adhesion molecules in cultured human coronary endothelial cells. J Vasc Res 2007;44:460-70.
66. Sato K, Nuki T, Gomita K, Weyand CM, Hagiwara N. Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndrome. Atherosclerosis 2010;213:33-9.
67. Katsiki N, Tziomalos K, Chatzizisis Y, Elisaf M, Hatzitolios AI. Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental? Atherosclerosis 2010;211:9-14.
68. Taylor F, Huffman MD, Mracedo AF, Moore TH, Burke M, Davey Smith G et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816.
69. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE et al. High dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59.
70. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001;103:926-33.
71. Cortellaro M, Cofrancesco E, Arbustini E, Rossi F, Negri A, Tremoli E et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost 2002;88:41-7.
72. Cipollone F, Fazia M, Iezzi A, Zucchelli M, Pini B, De Cesare D et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 2003;107:1479-85.
73. Martin-Ventura JL, Blanco-Colio LM, Gomez-Hernandez A, Muñoz-Garcia B, Vega M, Serrano J et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 2005;36:1796-800.
74. Verhoeven BA, Moll FL, Koekkoek JA, van der Wal AC, de Kleijn DP, de Vries JP et al. Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy. Stroke 2006;37:2054-60.
75. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006;26:2716-23.
76. Puato M, Faggin E, Rattazzi M, Zambon A, Cipollone F, Grego F et al. Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy. Stroke 2010;41:1163-8.
77. Lenglet S, Quercioli A, Fabre M, Galan K, Pelli G, Nencioni A et al. Statin treatment is associated with reduction in serum levels of receptor activator of NF-kB ligand (RANKL) and neutrophil activation in patients with severe carotid stenosis. Mediators Inflamm 2014; Art ID 720987.
78. Crouse JR, Byington RP, Bond MG, Espeland MA, Sprinkle JW, McGovern M et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome. Control Clin Trials 1992;13:495-506.
79. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994;90:1679-87.
80. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Liu C et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med 1996;124:548-56.
81. MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 1998;97:1784-90.
82. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001;103:1721-6.
83. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002;39:610-6.
84. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297:1344-53.
85. de Groot E, Jukema JW, Montauban van Swijndregt AD, Zwinderman AH, Ackerstaff RG, van der Steen AF et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998;31:1561-7.
86. Espeland MA, O'Leary DH, Terry JG, Morgan T, Evans G, Mudra H. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005;6:3.
87. Bedi US, Singh M, Singh PP, Bhuriya R, Bahekar A, Molnar J et al. Effects of statins on progression of carotid atherosclerosis as measured by carotid intimal-medial thickness: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 2010;15:268-73.
88. Huang Y, Li W, Dong L, Li R, Wu Y. Effect of statin therapy on the progression of common carotid artery intima-media thickness: an updated systematic review and meta-analysis of randomized controlled trials. J Atheroscler Thromb 2013;20:108-21.
89. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81.
90. Ainsworth DG, Blake C, Tamayo A, Beletsky V, Fenster A, Spence JD. 3D ultrasound measurement of change in carotid plaque volume. A tool for rapid evaluation of new therapies. Stroke 2005;36:1904-9.
91. Krasinski A, Chiu B, Spence JD, Fenster A, Parraga G. Three-dimensional ultrasound quantification of intensive statin treatment of carotid atherosclerosis. Ultrasound Med Biol 2009;35:1763-72.
92. Corti R, Fayad ZA, Fuster V, Worthley SG, Helft G, Chesebro J et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, non invasive magnetic resonance imaging. Circulation 2001;104:249-52.
93. Corti R, Fuster V, Fayad Z. Lipid Lowering by simvastatin induces regression of human atherosclerotic lesions: two years follow-up by high resolution non-invasive magnetic resonance imaging. Circulation 2002;106:2884-7.
94. Corti R, Fuster V, Fayad Z. Effects of aggressive versus conventional lipid-lowering by simvastatin on human atherosclerotic lesions. J Am Coll Cardiol 2005;46:106-12.
95. Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, Saam T et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients. Am Heart J 2008;155:584e1-8.
96. Lee JM, Wiesmann F, Shirodaria C, Leeson P, Petersen SE, Francis JM et al. Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging. Atherosclerosis 2008;197:951-8.
97. Migrino RQ, Bowers M, Harmann L, Prost R, LaDisa JF Jr. Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2011;3:13-37.
98. Tang TY, Howarth SPS, Miller SR, Graves MJ, Patterson AJ, U-King-Im JM et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009;53:2039-50.
99. Tahara N, Kai H, Ishibashi M, Kaida H, Baba K, Hayabuchi N et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006;48:1825-31.
100. Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol 2013;62:909-17.
101. McGirt MJ, Perler BA, Brooke BS, Woodworth GF, Coon A, Jain S et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. J Vasc Surg 2005;42:829-36.
102. Kennedy J, Quan H, Buchan AM, Ghali WA, Feasby TE. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke 2005;36:2072-6.
103. O'Neil-Callahan K, Katsimaglis G, Tepper MR, Ryan J, Mosby C, Ioannidis JP et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol 2005;45:336-42.
104. Perler BA. Should statins be given routinely before carotid endarterectomy? Perspect Vasc Surg Endovasc Ther 2007;19:240-5.
105. Perler BA. The effect of statin medications on perioperative and longterm outcomes following carotid endarterectomy or stenting. Semin Vasc Surg 2007;20:252-8.
106. Brooke BS, McGirt MJ, Woodworth GF, Chang DC, Roseborough GS, Freischlag JA et al. Preoperative statin and diuretic use influence the presentation of patients undergoing carotid endarterectomy: results of a large single-institution case-control study. J Vasc Surg 2007;45:298-303.
107. Heyer EJ, Mergeche JL, Bruce SS, Ward JT, Stern Y, Anastasian ZH et al. Statins reduce neurologic injury in asymptomatic carotid endarterectomy patients. Stroke 2013;44:1150-2.
108. Burgazli KM, Bilgin M, Kavukcu E, Mericliler M, Bohl N, Atmaca N. Which is a better treatment for carotid artery stenosis: stenting or endarterectomy? Eur Rev Med Pharmacol Sci 2013;1:1025-32.
109. Verzini F, De Rango P, Parlani G, Giordano G, Caso V, Cieri E et al. Effects of statins on early and late results of carotid stenting. J Vasc Surg 2011;53:71-9.
110. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006;28:26-35.
111. FDA.org-The Center for Health and Wellness. Available at: http://www.fda.org/drugs/drugssafety/ucm293101.htm.
112. Waters DD. Safety of high-dose atorvastatin therapy. Am J Cardiol 2005;96:69F-75F.
113. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 2012;43:2149-56.
114. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
115. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67.
116. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
117. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-64.
118. Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001;134:931-40.
119. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007;25:3462-8.
120. Bonovas S, Sitaras NM. Does pravastatin promote cancer in elderly patients? A meta-analysis. Can Med Assoc J 2007;176:649-54.
121. Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJ Med 2012;105:145-57.
122. Stone NJ, Robinson J, Lichtestein AH, Bairey Merz CN, Blum CB, Eckel RH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1-45.